Randomized Phase II Trial of Cetuximab, Bevacizumab, and Irinotecan Compared With Cetuximab and Bevacizumab Alone in Irinotecan-Refractory Colorectal Cancer: The BOND-2 Study
J Clin Oncol Saltz et al. 25:4557
Publisher’s Note
The October 10, 2007, article by Saltz et al, entitled “Randomized Phase II Trial of Cetuximab, Bevacizumab, and Irinotecan Compared With Cetuximab and Bevacizumab Alone in Irinotecan-Refractory Colorectal Cancer: The BOND-2 Study” (J Clin Oncol 25: 4557-4561, 2007) was published online September 17, 2007 with errors.
In the Results section, under Efficacy, the first and second sentences were given as:
“The median TTP of the CBI arm was 7.9 months, whereas that of the CB was 5.6 months. The response rates of the arms were 37% and 23%, respectively.”
While it should have read:
“The median TTP of the CBI arm was 7.3 months, whereas that of the CB was 4.9 months. The response rates of the arms were 37% and 20%, respectively.”
This has been corrected as of January 10, 2008.
|
